About Tamar
As a transformational executive and market access champion, Tamar Thompson has an impressive history in leading the complexities of health policy strategy and addressing the range of issues related to improving health outcomes. Tamar is a visionary thought leader who has leveraged her extensive pharmaceutical commercialization and launch strategy experience to work across the healthcare continuum and ensure optimal market entry and patient access to breakthrough and curative therapies.
Prior to joining Alexion, AstraZeneca Rare Disease, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb Company. Tamar also served as a policy advisor and consultant for three Washington, DC-based firms, ADVI, Kimbell & Associates and Avalere Health, where she managed a diverse portfolio of clients, including medical device, biotech, pharmaceutical, diagnostics, and specialty drug companies.
Preceding her time in Washington, DC, Tamar was Director of Health Policy & Reimbursement at Molecular Insight Pharmaceuticals (now Progenics), where she was charged with developing and launching reimbursement and market access strategy for cutting-edge molecular diagnostic and therapeutic treatments options. Additionally, she served in health policy and reimbursement leadership roles at GE Healthcare and Bracco Diagnostics.
Notably, her experience extends beyond the life sciences community as she also has held several senior leadership roles within the managed care sector for Humana and ValueOptions (now Carelon Behavioral Health).
Tamar serves on the board of directors for Avidity Bioscience, a clinical phase rare disease company. Concurrently, she sits on the executive committee and serves as Chair of the Board for MassBio; Director, Emeritus for Healthy Women, a patient empowerment organization; and the board of directors for the National Comprehensive Cancer Network Foundation. She also sits on the Schwartz Center (Mass General Hospital) Leadership Council.
Tamar holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress, California, and a Corporate Finance certification from Harvard Business School.
She is currently participating in the Berkeley NextGen Directors Program focused on corporate governance education and training for the next generation of diverse executives.